MARKET

MGTA

MGTA

MAGENTA THERAPEUTICS, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.14
-0.16
-1.42%
After Hours: 11.14 0 0.00% 16:00 09/18 EDT
OPEN
11.35
PREV CLOSE
11.30
HIGH
11.59
LOW
10.89
VOLUME
36.05K
TURNOVER
--
52 WEEK HIGH
21.00
52 WEEK LOW
5.31
MARKET CAP
382.88M
P/E (TTM)
-5.8264
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MGTA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MGTA News

  • FDA grants RMAT tag for Magenta cell therapy for inherited metabolic disorders
  • Seeking Alpha - Article.09/04 13:47
  • Magenta Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted To MGTA-456 For The Treatment Of Inherited Metabolic Disorders
  • Benzinga.09/04 12:34
  • Magenta Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to MGTA-456 for the Treatment of Inherited Metabolic Disorders
  • Business Wire.09/04 12:30
  • 60 Biggest Movers From Yesterday
  • Benzinga.08/22 09:12

More

Industry

Biotechnology & Medical Research
-0.65%
Pharmaceuticals & Medical Research
-0.05%

Hot Stocks

Name
Price
%Change

About MGTA

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics to transform hematopoietic stem cell transplants for patients with immune and blood-based diseases. It maintains a platform with integrated and modular approach, which aims to reboot the blood and immune systems. The Company’s products include MGTA-145, MGTA-456, E478, and G100. The Company also developing a pipeline of small molecules; biologics, including antibody drug conjugates; and a cell therapy, which transplant options for many more patients with autoimmune diseases, blood cancers and genetic diseases. The Company’s C100 program targets HSCs, immune cells, and disease-causing cells, the C200 program targets HSCs and disease-causing cells and the C300 program targets only immune cells. This is achieved by tuning the antibodies to specific cellular markers or receptors that are expressed on the particular cell types.
More

Webull offers Magenta Therapeutics Inc (MGTA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.